Zealand presented danegaptide as a case study on an

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Zealand presented danegaptide as a case study on an innovative novel peptide therapeutic at the 9th Annual Peptide Therapeutics Symposium in the U.S.

Copenhagen, 2014-10-29 08:52 CET (GLOBE NEWSWIRE) --

  • Danegaptide is being evaluated in a Zealand-designed clinical Phase II PoC trial as a potential first-ever medicine against ischemic reperfusion injuries. More than 50% of the planned 600 patients with acute myocardial infarction are now enrolled and treated in the trial, running on schedule

Copenhagen, 29 October 2014 – Zealand Pharma A/S (“Zealand”) (Nasdaq Copenhagen: ZEAL) informs that the company presented a case study on danegaptide as a novel and innovative peptide therapeutic and potential first-in-class gap junction modifier at the 9th Annual Peptide Therapeutics Symposium, which recently took place in La Jolla, California, the U.S.

The Symposium is an annual scientific meeting that brings together world leaders in peptide research from academia and the biopharmaceutical industries, focusing on core advances in peptide-based drug discovery and therapeutic candidate development. 

In the presentation, entitled “ Danegaptide - Potential First and Best in Class Peptide Medicine for Prevention of Myocardial Reperfusion Injury ”, Rie Schultz Hansen, Principal Scientist at Zealand, outlined that danegaptide has both anti-arrhythmic and cell-protective properties, and that this novel peptide has been shown to protect cardiac tissue in preclinical models of ischemic reperfusion injuries, causing significant reductions in infarct sizes in both dogs and pigs. Further, she presented the design and status of the ongoing clinical Phase II Proof-of-concept trial on danegaptide, conducted by Zealand in collaboration with Rigshospitalet in Denmark, one of Europe’s leading cardiac centres with key expertise in Acute Myocardial Infarction (AMI). To date, more than 50% of the targeted 600 patients with an AMI have been enrolled and treated, and the study is on track to complete and report results in H2 2015.

Danegaptide was invented by Zealand and has been shown to be both very safe and well-tolerated in three clinical Phase I trials. In October 2013, Zealand started the Phase II Proof-of-Concept study to evaluate the efficacy and safety of danegaptide in the protection against cardiac tissue damage from ischemic reperfusion injuries in patients with an AMI, who are undergoing percutaneous coronary intervention (PCI). The study is designed as a randomized, double-blind, placebo-controlled trial evaluating two different doses of danegaptide against placebo with a three months primary endpoint of change in myocardial salvage index as a validated measure of cardiac infarct size.

Commenting on the presentation, Dr. Torsten Hoffmann, Executive Vice President and Chief Scientific Officer of Zealand, said:

“ Zealand’s invitation to this prestigious event is a recognition of the company’s competences and position in the field of innovative peptide R&D. It also reflects the attention that danegaptide attracts, and we are thrilled to have been given this opportunity to show-case the ground-breaking work we have done so far and the potential of danegaptide as a first-ever therapeutic for the protection of cardiac damage in patients with an AMI. There are estimated to be 750,000 incidents of AMI annually in the seven major markets by 2020, and reperfusion injuries represent an area of large unmet medical need for these patients .”

In collaboration with the Copenhagen University, Zealand also has a project ongoing to investigate the full therapeutic potential of danegaptide as a novel approach in the protection of tissue from ischemic reperfusion injuries. The project was selected by the Danish Innovation Fund (InnovationsFonden) to receive a DKK 1 million grant.

***

For further information, please contact:

David Solomon, President and Chief Executive Officer
Tel: +45 22 20 63 00

Hanne Leth Hillman, Vice President,
Head of Investor Relations & Corporate Communications

Tel: +45 50 60 36 89, email: hlh@zealandpharma.com

About danegaptide

Danegaptide is a therapeutic peptide invented by Zealand, exerting effect via activation of gap junction communication channels between cells, and demonstrating both anti-arrhythmic and cell protective properties.

In a pre-clinical model of acute myocardial infarction (AMI), i.e. an acute blood clot in the heart, danegaptide has shown dose-dependent significant reductions in infarct size after reperfusion. In another relevant translational model of reperfusion injury associated with an AMI, danegaptide significantly reduced infarct size compared to immediate full reperfusion1. Results from an extensive Phase I program, including three (3) individual studies with a total of 153 subjects, showed that danegaptide was safe and well tolerated.

Reference

1 Journal of the American College of Cardiology: Volume 61, Issue 10, Supplement, Page E67, 12 March 2013

About Ischemic Reperfusion Injury

In case of an acute myocardial infarction (AMI), or a heart attack, a blood clot blocks the blood flow to important parts of the heart for a longer period of time (ST segment elevation myocardial infarction, STEMI). The standard treatment of AMI today is different types of interventions aimed at re-establishing blood flow to the ischemic myocardium, thereby limiting the size of the infarct. Percutaneous coronary intervention (PCI), also called balloon dilatation, is the most common. In 2020, the incidence for STEMI is predicted to be 756.700 in US, EU and Japan combined, and approximately 80% of STEMI patients undergo PCI procedure.

Interventional treatment is the most effective method to restore blood flow or re-perfuse the heart, thereby reducing the infarct size and improving the outcome for patients with a STEMI. The process of myocardial reperfusion however, can paradoxically itself induce further cardiac tissue damage, a phenomenon known as myocardial reperfusion injury.

To date there are no marketed pharmacological treatments for the prevention of reperfusion injury. Both mechanical pre- and post-conditioning (series of repetitive interruptions of the coronary blood flow during the PCI procedure) seem to protect cardiomyocytes during reperfusion. Reducing infarct size by 15% corresponds to a reduction in six month absolute mortality of 1% making this a meaningful marker for long term outcomes for patients.

About Zealand Pharma

Zealand Pharma A/S (“Zealand”) (Nasdaq Copenhagen: ZEAL) is a biotechnology company based in Copenhagen, Denmark. Zealand has leading expertise in the discovery, design and development of novel peptide medicines, in-house competences in clinical trial design and management and a therapeutic focus on cardio-metabolic diseases. The company has a broad portfolio of therapeutic products – proprietary and partnered.

Zealand’s first invented medicine, lixisenatide, a once-daily prandial GLP-1 agonist for the treatment of Type 2 diabetes, is marketed world-wide ex-US as Lyxumia® and in Phase III development as a single-injection combination with Lantus® (LixiLan), both under a global license agreement with Sanofi. US regulatory filing for both products is planned for 2015 ─ summer for Lyxumia® and as early as end 2015 for LixiLan.

Zealand is advancing a pipeline of proprietary, next-generation therapies, including danegaptide (prevention of Ischemic Reperfusion Injury) in addition to several preclinical programs. Partnering represents an important component of strategy to share development risk in large clinical trials, to provide funding and to commercialize the company’s products. Zealand currently has global license agreements and partnerships with Sanofi, Boehringer Ingelheim, Eli Lilly and Helsinn Healthcare.

For further information: www.zealandpharma.com           Follow us on Twitter @ZealandPharma  

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Yatsen’s November 25 Report Is the Real Beauty Test

Updated Category News Views 0

Beauty shelves can hide a lot of sins, but earnings day tends to drag them into fluorescent light. Yatsen will release unaudited third-quarter 2026 financial results before the U.S. market opens on Wednesday, November 25, then management will take questions at 7:30 a.m. Eastern Time. For anyone following NYSE:YSG, this is not a results story yet. It is a calendar marker,...

Continue Reading
Zunyi’s History Tour Carries China’s Story Overseas

Updated Category News Views 46

China’s national story does not travel overseas by accident; it gets carried by visitors, monuments, rail lines, rivers and carefully chosen questions. The Zunyi News and Media Center report follows Tayyab, a Pakistani PhD student in aerospace engineering at Peking University, as he heads from Beijing to Zunyi, Guizhou, carrying a copy of Edgar Snow’s Red Star Over...

Continue Reading
Vertex Extends Genomics Pact With $220M in Potential

Updated Category News Views 49

Eight years is long enough to separate a useful science partner from a glossy slide deck, and Vertex’s decision to add four more years with Genomics deserves attention. This is not a splashy acquisition, nor is it a clean revenue number investors can plug into next quarter’s model. It is a deeper commitment to the slow, expensive, wonderfully unforgiving business of...

Continue Reading
Exiger's CEO Honored for Military Support Excellence

Updated Category News Views 118

Recognizing Civilian and Military Leadership When you hear "recognition in the military sector," it isn't just a pat on the back. It's a whole parade of brass hats and high-flyers giving their nods. So, November 10th wasn't just any regular day—Brandon Daniels, CEO of Exiger, gets a shiny, prestigious Five-Star Award for his "extraordinary support" of our military...

Continue Reading
Photocure Opens a New Access Route for Hexvix Patients

Updated Category News Views 25

Forty-plus markets just moved from “not available” toward a workable route for individual bladder cancer patients, and that is the real substance of Photocure’s new arrangement with Clinigen. This is not a sweeping product launch, nor is it an approval announcement dressed up in confetti. It is a Named Patient Program, which matters because the regulatory plumbing...

Continue Reading
Benicia's Bold Move to Streamline Permitting Pays Off

Updated Category News Views 171

Award-Winning Innovation from Benicia Benicia, California, shoots ahead of the pack by scooping up a highly coveted Helen Putnam Award for Excellence. Why? They chopped down bureaucracy like a lumberjack with a new ax by ushering in a digital revolution for their permitting process. Make no mistake, folks, this ain’t just a pat on the back—it's a blueprint for cities...

Continue Reading
Unilumin's APEC 2026 Showcase Is a Useful Field Test

Updated Category News Views 65

Few sales pitches get stress-tested by a thousand journalists, a major airport, and a leaders' summit all at once. That is the useful part of Unilumin's role as an official sponsor of APEC 2026 in Shenzhen. The company says its LED systems were installed across summit venues, the media center, transportation hubs, and city landmarks as the 33rd APEC Economic Leaders'...

Continue Reading
CATL Makes Its APEC Case Beyond the Electric Car Market

Updated Category News Views 10

A 99-Second Pitch With Bigger Ambitions Battery swapping got a rare moment in the geopolitical sunlight at Shenzhen's APEC CEO Summit, and CATL was plainly trying to make that moment count. Dr. Robin Zeng, the company's founder, chairman and chief executive, used the opening business dialogue to argue that the Asia-Pacific region holds more opportunity than trouble. Fair...

Continue Reading
Diwali at Heritage Shows the Real Estate Community Test

Updated Category News Views 89

Fireworks do not sell a townhome by themselves, but belonging can sure help close the distance between a brochure and a serious purchase. Heritage at South Brunswick recently held a Diwali celebration sponsored by American Properties at South Brunswick LLC, bringing homeowners, families, and the builder's team into the same room for an evening of food, music, dancing,...

Continue Reading
Vertiv's 800 VDC Push Gives AI Builders More Choices

Updated Category News Views 321

Electricity is becoming the awkward roommate inside every serious AI buildout, and Vertiv is trying to move it out of the rack before it eats the whole house. The company has expanded its 800 VDC offering beyond the PowerDirect 5000 rack product introduced in May 2026, laying out systems for the rack, the AI compute pod, and the full data hall. For investors following...

Continue Reading

Top 5 Most Recently Viewed Articles

GRAX Honored as Cybersecurity Innovator by BostInno Awards

Updated Category News Views 66

GRAX Recognized as a Leader in Cybersecurity GRAX, Inc., well-known for its innovation in Salesforce data management and protection, has recently earned an esteemed recognition as a 2024 Fire honoree in cybersecurity from BostInno. This award celebrates companies that are driving innovation in the Boston area, emphasizing GRAX's role as a pioneer in data security....

Continue Reading
i2Cool and Marubeni Join Forces for Revolutionary Cooling Tech

Updated Category News Views 286

i2Cool and Marubeni Forge Strategic Partnership i2Cool, a pioneering company in the realm of electricity-free cooling technology, has established a significant global partnership with Marubeni, a prominent trading company from Japan. This collaboration is designed to facilitate the widespread adoption of electricity-free cooling technologies, concentrating particularly on...

Continue Reading
Jasper Therapeutics Upcoming Investor Conferencs - September 2024

Updated Category News Views 82

Jasper Therapeutics to Showcase Innovations at September Events Jasper Therapeutics, Inc. (NASDAQ: JSPR), a leader in biotechnology, is preparing for a series of investor conferences this September. The company is particularly excited to discuss briquilimab, an innovative antibody therapy designed to treat c-Kit (CD117) driven mast cell diseases, including chronic...

Continue Reading
Tech Sector Thrives as Meta Drives Nasdaq-100 to New Heights

Updated Category News Views 303

Tech Sector Soars with New Nasdaq-100 Records The Nasdaq-100 has reached an unprecedented high of 22,191.37, highlighting the unyielding strength of tech stocks. The renowned Invesco QQQ Trust (NASDAQ: QQQ) has also achieved a 52-week peak, reaching $540, demonstrating the energetic rally across the technology market. Meta Platforms Inc's Remarkable Performance Meta...

Continue Reading
Millicom Advances Infrastructure Sale and Special Dividend Plans

Updated Category News Views 207

Millicom Announces Infrastructure Deal Progress Millicom International Cellular S.A. (NASDAQ: TIGO) has made significant strides in its transaction with SBA Communications. The company recently revealed the partial closing of its sale involving LATI International S.A., the holding company for its mobile passive infrastructure assets in Central America. This deal has...

Continue Reading